Targeting tumor associated macrophages (TAMs) reprograms tumor immune microenvironment to promote solid tumor immunotherapy.

This document discusses the limitations of cancer immunotherapy using PD-1/PD-L1 immune checkpoint blockade (ICBs) and the importance of understanding the tumor immune microenvironment (TIME). The document focuses on the role of tumor-associated macrophages (TAMs) in solid tumors and their impact on immunotherapy efficacy. It highlights the potential of targeting the immune receptor SIRPA on TAMs as a promising strategy for cancer immunotherapy. The document also explores the role of TAMs in glioblastoma multiforme (GBM) and suggests targeting the immune checkpoint Siglec-9 on TAMs as a potential treatment for GBM. The overall goal is to reprogram the tumor immune microenvironment to enhance the effectiveness of immunotherapy. [Extracted from the article]